RxDoctor Payments Data

Paul Sue

Pediatric Infectious Diseases · New York, NYNPI 1447571690

Payments from drug & device makers

What this record shows

This record is dominated by travel and lodging: $1,833 of the $1,927 with a category attached, or 95.1%. Every reported general payment came from a single manufacturer, Merck.

$1,927in general payments, 2019–2025

Across 8 payments — averaging $240.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$2K
$571,356in research payments, 2019–2025

Across 93 payments — averaging $6143.61 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Merck$351K
  • Gilead$160K
  • Astellas Pharma Global Development$60K

What the payments were for

  • Travel & lodging$1,83395%
  • Food & beverage$955%

General payments by program year

19
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Merck8$1,927

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,927 in reported general payments places this provider in the 70th percentile of 73 pediatric infectious diseases providers in New York.

See all pediatric infectious diseases providers in New York →

Other pediatric infectious diseases in New York

See the full list for New York →

Where these figures come from

Is this you, or does something look wrong? →